Compare Gilead Sciences, Inc. (GILD) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Millicom International Cellular S.A. Common Stock — how do they compare? Gilead Sciences, Inc. trades at $155.08 (market cap $183.41B), while Millicom International Cellular S.A. Common Stock trades at $80.5 (market cap $13.34B). The key difference: Gilead Sciences, Inc. is far larger — about 13.7× Millicom International Cellular S.A. Common Stock's market cap, and Millicom International Cellular S.A. Common Stock pays the higher dividend (3.77%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| GILD | TIGO | |
|---|---|---|
Market Cap | $183.41B | $13.34B |
Volume | 5,557,651 | 1,586,684 |
Sector | Health | Media |
52-Week High | $155.80 | $104.31 |
52-Week Low | $117.85 | $45.81 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $206.48B | $24.38B |
Dividend Yield | 2.22% | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $153.54, up 2.07% today, near its consensus price target of $153.13. The stock shows a bullish technical trend with strong moving average signals. Recent earnings beat expectations in Q2 2026, though the company posted a net loss. Revenue growth is steady, with 2025 revenue at $29.44B, but profitability metrics like ROE and net income margin are negative. Positive news includes expanded HIV drug access in Latin America.
The outlook is mixed: analyst consensus is bullish with 65.52% buy ratings, but high debt and negative margins pose risks. Key catalysts include oncology pipeline advances and HIV franchise growth, while execution risks and competitive pressures remain concerns for investors.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
